Group 1 - Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases, respiratory diseases, and metabolic disorders [3] - The company will participate in the Biomed Forum on February 4, 2025, in Paris, which is an annual event aimed at connecting biotech and medtech companies with institutional investors [2] - The participation in the forum will provide Biophytis an opportunity to engage with French and European investors and share updates on its latest developments and outlook for 2025 [2] Group 2 - Biophytis is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts, USA, and Brazil, with its ordinary shares listed on Euronext Growth Paris and American Depositary Shares on the OTC market [3]
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference